This trial is testing a new cancer treatment combining a new drug with standard chemotherapy, to see if it improves remission rates in patients with a certain type of lymphoma.
1 Primary · 8 Secondary · Reporting Duration: Baseline to end of study (up to 2 years)
54 Total Participants · 1 Treatment Group
Primary Treatment: R-CHOP chemotherapy · No Placebo Group · Phase 2
Age 18+ · All Participants · 8 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: